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The original version of this article unfortunately contained mistakes. There is an incorrect unit of IL-6 in Fig. [1](#Fig1){ref-type="fig"} and Supplementary Table 1. It should be pg/mL rather than ng/mL. The corrected Fig. [1](#Fig1){ref-type="fig"} and Supplementary Table 1 can be found below. The authors apologize for the mistakes.Fig. 1**a** Age distribution of patients with confirmed COVID-19; **b** key laboratory parameters for the outcomes of patients with confirmed COVID-19; **c** interval from onset of symptom to death of patients with confirmed COVID-19; **d** summary of the cause of death of 68 died patients with confirmed COVID-19

Supplementary Table 1: Summary of clinical features and laboratory results of the patients with confirmed COVID-19**Normal RangeDied**\
**(N = 68)Discharged**\
**(N = 82)p-valueDemographics**Age, years67 (15-81)50 (44-81)\<0.001SexMale49 (72%)53 (65%)Female19 (28%)29 (35%)Comorbidities43 (63%)34 (41%)0.01Hypertension29 (43%)23 (28%)0.07Cardiovascular disease13 (19%)0\<0.001Diabetes12 (18%)13 (16%)0.88Cerebrovascular disease7 (10%)5 (6%)0.49Chronic obstructive pulmonary disease2 (3%)1 (1%)0.59Chronic kidney disease2 (3%)00.20Malignancy2 (3%)1 (1%)0.59Chronic liver disease1 (1%)3 (4%)0.63Connective tissue disease1 (1%)00.45**Signs and Symptoms**Fever59 (87%)68 (83%)0.67Cough51 (75%)59 (72%)0.81Sputum production29 (43%)25 (30%)0.17Fatigue15 (22%)22 (27%)0.63Myalgia9 (13%)10 (12%)1Haemoptysis3 (4%)00.09Dyspnea59 (87%)51 (62%)0.001Respiratory failure58 (85%)13 (16%)\<0.001ARDS55 (81%)7 (9%)\<0.001Acute kidney injury21 (31%)2 (2%)\<0.001Infection11 (16%)1 (1%)0.002**Treatments**ICU admission30 (44%)11 (13%)\<0.001High flow nasal cannula31 (46%)10 (12%)\<0.001Non-invasive mechanical ventilation46 (68%)5 (6%)\<0.001Invasive mechanical ventilation25 (37%)0\<0.001ECMO7 (10%)00.003CRRT5 (7%)00.02Prone position mechanical ventilation3 (4%)00.09Antiviral treatment33 (49%)55 (67%)0.05Antibiotic treatment63 (93%)80 (98%)0.66Antifungal treatment12 (18%)5 (6%)0.04Glucocorticoid treatment31 (46%)22 (27%)0.02Time from onset of symptom to start of Glucocorticoid treatment, days11.7 (6.9)11.4 (4.4)0.89Time from hospital admission to start of Glucocorticoid treatment, days1.5 (1.2)3.2 (2.7)0.01Glucocorticoid treatment duration, days7.2 (6.7)7.0 (5.0)0.92Supportive therapy45 (66%)18 (22%)\<0.001Length of stay, days7.4 (5.5)12.3 (4.4)\<0.001**Laboratory Findings**Time from onset of symptom to test, days11.6 (6.8)9.8 (4.3)0.07White blood cell count, × 10^9^/L3.50-9.5010.62 (4.76)6.76 (3.49)\<0.001Lymphocyte count, × 10^9^/L1.10-3.200.60 (0.32)1.42 (2.14)\<0.001Haemoglobin, g/L130.0-175.0127.0 (16.7)127.6 (16.3)0.82Platelet count, × 10^9^/L125.0-350.0173.6 (67.7)222.1 (78.0)\<0.001Albumin, g/L35.0-52.028.8 (3.8)32.7 (3.8)\<0.001Alanine aminotransferase, U/L9.0-50.0170.8 (991.6)48.68 (83.1)0.35Aspartate aminotransferase, U/L15.0-40.0288.9 (1875.5)40.7 (57.8)0.31Total bilirubin, μmol/L0.0-26.018.1 (10.7)12.8 (6.8)0.001Blood urea nitrogen, mmol/L3.1-8.08.65 (4.5)5.11 (2.1)\<0.001Creatinine, umol/L59.0-104.091.2 (56.2)72.1 (22.2)0.02Creatine kinase, U/L50.0-310.0319.4 (838.5)231.7 (862.3)0.56Lactate dehydrogenase, U/L120.0-250.0905.8 (2619.1)297.9 (110.4)0.08Cardiac troponin, pg/mL2.0-28.030.3 (151.0)3.5 (6.2)\<0.001Myoglobin, ng/mL0.0-146.9258.9 (307.6)77.7 (136.1)\<0.001C-reactive protein, mg/L0.0-5.0126.6 (106.3)34.1 (54.5)\<0.001Interleukin-6, pg/mL0.0-7.011.4 (8.5)6.8 (3.61)\<0.001Serum ferritin, ng/mL21.8-274.71297.6 (1030.9)614.0 (752.2)\<0.001Data are n (%), n/N (%), mean (SD), and median (IQR). When the data were normally distributed, continuous variables were then described using median and interquartile range (IQR) values.ARDS = acute respiratory distress syndrome. ECMO = extracorporeal membrane oxygenation. ICU = intensive care unit. CRRT = continuous renal replacement therapy.
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